Revolutionary Outcomes Unveiled in Field Medical's First-in-Human Trial of Pulsed Field Ablation Technology

Innovative Advances in Cardiac Ablation Technology

Field Medical, Inc., a pioneer in high-voltage focal pulsed field ablation (PFA) technology, has recently published compelling results from their first-in-human trials, dubbed the Field PULSE trial. This significant clinical research presents innovative approaches in treating complex cardiac arrhythmias and shows a 94.2% durability rate for pulmonary vein isolation (PVI) at the twelve-month mark.

Overview of the Field PULSE Trial

The results were initially unveiled during the prestigious HRX Live 2026 conference, showcasing the rapid advancements in the FieldForce™ PFA System—a technology specifically crafted to address the challenges associated with cardiac ablation. By focusing on delivering ablation with unparalleled speed and precision, this system holds promise for significantly improving treatment outcomes for patients suffering from arrhythmias.

The trial highlights an impressive median procedural time of just 13 minutes for PVI ablation, with the fastest recorded time being an astonishing 7.7 minutes. This rapid efficiency bolsters the argument for the viability of this innovative technology in clinical settings.

Key Results and Findings

1. Durability of PVI: With an optimized waveform employed in procedures, 94.2% durability was observed across individual veins, indicating a progressive enhancement thanks to the evolution of waveform technology.
2. Procedural Efficiency: The average time to achieve PVI was remarkably short, with clear benefits for both clinicians and patients, reducing the time spent under catheters—an important factor for overall procedure attractiveness.
3. Flexibility in Treatment: Nearly half (49%) of patients included in the trial were afforded non-pulmonary vein ablation for additional atrial targets. This flexibility marks a significant advance in the potential scope of atrial ablation procedures, catering to complex patient needs.
4. Safety Profile: Encouragingly, no primary safety events were noted throughout the trial, reinforcing the safety of the FieldForce system. Furthermore, 80% of participants maintained freedom from atrial arrhythmias at the 12-month follow-up, showcasing long-term benefits.

Expert Insights

Dr. Vivek Reddy, co-principal investigator and lead electrophysiologist with Mount Sinai Health System, emphasized the groundbreaking nature of these findings, stating, "Field PULSE demonstrates the feasibility of truly instantaneous focal PFA. Reducing the application time to less than 200 milliseconds lessens the dependence on prolonged catheter stability while promoting customizable ablation approaches. Such advances in procedural efficiency, safety, and targeted isolation reinforce our commitment to advancing this promising methodology."

Mark A. Turco, M.D., President and CEO of Field Medical, echoed these sentiments, noting, "Field PULSE illustrates that our high-voltage focal PFA architecture can support an instantaneous workflow in the atrium. This adds significant clinical evidence towards a differentiated PFA platform capable of addressing diverse cardiac challenges with pace and precision."

Future Directions

As Field Medical continues to refine their pioneering methodologies in pulsed field ablation, the results from the Field PULSE trial are expected to shape how arrhythmias are treated globally. This innovative technology could redefine the standard of care, bolstering treatment efficacy and enhancing patient quality of life.

In summary, the promise shown in the Field PULSE trial underscores the potential of high-voltage focal PFA systems to revolutionize treatment paradigms in cardiac care. By harnessing a blend of efficiency, versatility, and safety, Field Medical is paving the way for the future of cardiac ablation.

For more information on Field Medical and their pioneering work, you can visit their website at Field Medical.